National and Kapodistrian University of Athens
Παρουσία μεταλλοενζύμων τύπου VIM-1 σε στελέχη Klebsiella pneumoniae από ασθενείς με μικροβιαιμία: κλινική σημασία και παράγοντες κινδύνου
Abstract
dc:descriptionIntroduction: VIM-1-producing K. pneumoniae (VPKP) is an emerging pathogencausing life-threatening infections. The present study was conducted to identify thefactors associated with bloodstream infections (BSI) caused by VPKP and to evaluate theimportance of VIM production on outcome.Materials and methods: A prospective observational study was conducted in threetertiary care hospitals located in Athens, Greece, from 2004 to 2006. Consecutive patientswith K. pneumoniae BSI were identified and followed up until discharge or death.Pertinent information was abstracted in a pre-designed form. Antimicrobial susceptibilitytesting was performed by Etest. Microbial characteristics including MBL production, blagene carriage and chromosomal types were examined. The data were analyzed to assessfor risk factors associated with VPKP BSIs and 14-day mortality.Results: A total of 178 patients with Klebsiella pneumoniae BSIs were identified; 67(37.6%) were infected with a VPKP and 111 (62.4%) with a non-VPKP. MICs ofimipenem for VPKP varied from the susceptible range to high-level resistance; 19 isolates were resistant to imipenem and 48 susceptible, whereas none of the non-VPKPexhibited resistance to carbapenems. VPKP were invariably multi-drug resistant. Prioruse >3 classes of antibiotics (OR, 12.6; 95% CI, 2.17-73.27; P=0.01), prior use ofcarbapenems (OR, 2.83, 95% CI 1.07-7.49, P 0.03) and stay in ICU (OR, 6.78, 95% CI2.69-17.06, P<0.001) were independently associated with VPKP BSIs. VIM productionhad no effect on portality whereas resistance to carbapenems (MICs of imipenem andmeropenem >4 μg/ml) had a sugnificant impact on 14-day mortality. Patient age, theseverity of underlying disease, the source of bacteremia, and inappropriate empirical ordefinitive thereapy had a trend of higher mortality. By entering in the cox regressionmodel all of the host- and infection-related variables for which the P values where ≤ 0.10in the univariate analysis, an MIC of carbapenems of >4 μg/ml (HR, 2.83; 95% CI, 1.08-7.41; P= 0.035), age (HR, 1.03; 95% CI, 1.01-1.06; P= 0.021) and rapidly fatal undelyingdisease (HR, 2.84; 95% CI, 1.26-6.39; P= 0.012) where associated with 14-daymortality. After adjustment for “inappropriate empirical treatment” or “inappropriate definite treatment,” the effect of carbapenem resistance on 14-day mortality was reducedto a level of nonsignificance, while the HRs and the P values of the other variablesremained essentially unchanged. The lowest mortality (8.3%) was observed in the groupof patients who received combination therapy with two active drugs, one of which wascarbapenem and the other either colistin or an active aminoglycoside, whereas therapywith one active drug (a carbapenem, colistin, or an aminoglycoside) resulted in mortalityrate similar to that observed in patients who received inappropriate therapy (no activedrug).Conclusion: VPKP have spread widely in our region and cause life-threateninginfections mainly in ICU patients who had prior exposure to carbapenems. VPKP BSIsare associated with high mortality rates when the infecting organism is resistant tocarbapenems.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2013
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Petrikkos, Panagiotis
- Πετρίκκος, Παναγιώτης
Subjects
dc:subject × 11Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/38984